What is the BEAM stock price?

Beam Therapeutics Inc. (BEAM) last available close: $26.33, as of 11/3/26. Prices on Cylvex may be delayed.

How many analyst price targets for BEAM were reached?

3 of 12 published price targets for BEAM were reached within 12 months (25% reached); 6 are still open. Counts only — firm names and target values are shown to signed-in members.

How many firms publish price targets or ratings on BEAM?

14 firms have published price targets or ratings on BEAM that Cylvex tracks. Counts only — firm names and target values are shown to signed-in members.

Is this investment advice?

No. Cylvex is an educational and informational platform; nothing on this page is investment, financial or trading advice. Past analyst targets do not predict future results.

NASDAQ

Updated Nov 3, 7:59 PM ET

BEAM

Beam Therapeutics Inc.

$26.41CS band Mixed

+$0.46 (1.78%) At close $26.33 · Today

☾After Hours +$0.08 (0.31%) Nov 3, 7:59 PM ET

About BEAM

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Why it moved

Filed an 8-K today reporting results of operations · per SEC

Sources: SEC

From SEC filing · Not investment advice

Daily prices Fundamentals

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Sentiment

No sentiment yet

Votes and Bull · Bear posts, 24h. At least 5 are needed.

How do you feel about BEAM?

Latest news

News ›

Zacks Investment Research10/29/26

Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?

Beam Therapeutics (BEAM) shares surged 15.6% following positive early-stage data for its experimental gene-editing treatment BEAM-301 for glycogen storage disease type Ia. The treatment showed improvements in fasting tolerance and glucose control in six patients, with two patients no longer requiring daily starch supplements.

VIR

Headlines open the publisher's site.

Board · 0 threads

Open board ›

CYLVEXCylvex· 11/3/26

BEAM · results filed (8-K, Nov 3, 8:34 AM ET) · reactions

$BEAM filed an 8-K with results (Item 2.02) at 8:34 AM ET on Tue, Nov 3.

Vote

Community opinions, not advice. Posts with a target get a receipt. How receipts work ›